Etude de phase II randomisée, non comparative d’un anti-PD-L1 (atezolizumab) ou de la chimiothérapie en seconde ligne de traitement chez des patients présentant un cancer bronchique à petites cellules
IFCT-1603
- Publications:
- A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT 1603 Trial
- A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 Trial
- Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
- Etude de phase II randomisée non comparative de l'anti-PD-L1 atézolizumab versus chimiothérapie comme traitement de deuxième ligne chez les patients atteints d'un cancer du poumon à petites cellules (CBPC) : résultats de l'essai IFCT-1603
- Synopsis: IFCT-1603_Synopsis_v1.3_090217.pdf